JP2022509372A - 血液脳関門輸送の促進のためのヒト化され安定化されたfc5バリアント - Google Patents
血液脳関門輸送の促進のためのヒト化され安定化されたfc5バリアント Download PDFInfo
- Publication number
- JP2022509372A JP2022509372A JP2021547670A JP2021547670A JP2022509372A JP 2022509372 A JP2022509372 A JP 2022509372A JP 2021547670 A JP2021547670 A JP 2021547670A JP 2021547670 A JP2021547670 A JP 2021547670A JP 2022509372 A JP2022509372 A JP 2022509372A
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- variable domain
- antibody variable
- position corresponding
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Toxicology (AREA)
- Psychiatry (AREA)
- Zoology (AREA)
- Hospice & Palliative Care (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Orthopedic Medicine & Surgery (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024176055A JP2024177499A (ja) | 2018-10-29 | 2024-10-07 | 血液脳関門輸送の促進のためのヒト化され安定化されたfc5バリアント |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862751962P | 2018-10-29 | 2018-10-29 | |
| US62/751,962 | 2018-10-29 | ||
| PCT/US2019/058286 WO2020092202A2 (en) | 2018-10-29 | 2019-10-28 | Humanized and stabilized fc5 variants for enhancement of blood brain barrier transport |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024176055A Division JP2024177499A (ja) | 2018-10-29 | 2024-10-07 | 血液脳関門輸送の促進のためのヒト化され安定化されたfc5バリアント |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022509372A true JP2022509372A (ja) | 2022-01-20 |
| JP2022509372A5 JP2022509372A5 (cg-RX-API-DMAC7.html) | 2022-11-01 |
Family
ID=68582454
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021547670A Pending JP2022509372A (ja) | 2018-10-29 | 2019-10-28 | 血液脳関門輸送の促進のためのヒト化され安定化されたfc5バリアント |
| JP2024176055A Pending JP2024177499A (ja) | 2018-10-29 | 2024-10-07 | 血液脳関門輸送の促進のためのヒト化され安定化されたfc5バリアント |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024176055A Pending JP2024177499A (ja) | 2018-10-29 | 2024-10-07 | 血液脳関門輸送の促進のためのヒト化され安定化されたfc5バリアント |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20220089704A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3873934A2 (cg-RX-API-DMAC7.html) |
| JP (2) | JP2022509372A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20210111242A (cg-RX-API-DMAC7.html) |
| CN (1) | CN113508135A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2019371814A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112021008105A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3117409A1 (cg-RX-API-DMAC7.html) |
| EA (1) | EA202191179A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL282677A (cg-RX-API-DMAC7.html) |
| MA (1) | MA54070A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2021004772A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020092202A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111201030B (zh) | 2017-07-25 | 2024-11-01 | 真和制药有限公司 | 通过阻断tim-3和其配体的相互作用治疗癌症 |
| KR20210124308A (ko) | 2019-01-30 | 2021-10-14 | 트루바인딩 아이엔씨. | 항-gal3 항체 및 이의 용도 |
| MX2022014786A (es) | 2020-05-26 | 2023-01-16 | Truebinding Inc | Metodos para tratar enfermedades inflamatorias mediante el bloqueo de galectina-3. |
| EP4172194A1 (en) * | 2020-07-31 | 2023-05-03 | CureVac SE | Nucleic acid encoded antibody mixtures |
| US20250222129A1 (en) * | 2022-03-21 | 2025-07-10 | National Research Council Of Canada | Lipid Based Nanoparticles for Targeted Gene Delivery to the Brain |
| CN116650660B (zh) * | 2023-07-27 | 2023-11-03 | 上海偌妥生物科技有限公司 | 制备抗体偶联小分子药物的方法及其应用 |
| CN122167571A (zh) * | 2024-12-06 | 2026-06-09 | 合肥综合性国家科学中心大健康研究院 | 抗vmat2的抗体或其抗原结合片段及其组合物和应用 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018007950A1 (en) * | 2016-07-06 | 2018-01-11 | National Research Council Of Canada | Humanized antibodies transmigrating the blood-brain barrier and uses thereof |
| WO2018109663A1 (en) * | 2016-12-12 | 2018-06-21 | National Research Council Of Canada | Antibody variants transmigrating the blood-brain barrier and uses thereof |
| WO2018138709A1 (en) * | 2017-01-30 | 2018-08-02 | National Research Council Of Canada | Blood-brain barrier transmigrating compounds and uses thereof |
Family Cites Families (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| GB8620926D0 (en) | 1986-08-29 | 1986-10-08 | Delta Biotechnology Ltd | Yeast promoter |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| CA2441903C (en) * | 2000-05-26 | 2012-07-31 | National Research Council Of Canada | Single-domain brain-targeting antibody fragments derived from llama antibodies |
| EP1673395A1 (en) | 2003-10-15 | 2006-06-28 | PDL BioPharma, Inc. | Alteration of fc-fusion protein serum half-lives by mutagenesis of positions 250, 314 and/or 428 of the heavy chain constant region of ig |
| US8546543B2 (en) | 2004-11-12 | 2013-10-01 | Xencor, Inc. | Fc variants that extend antibody half-life |
| WO2006130374A2 (en) | 2005-05-27 | 2006-12-07 | Biogen Idec Ma Inc. | Tweak binding antibodies |
| PT2548560E (pt) | 2005-06-23 | 2015-09-22 | Isis Pharmaceuticals Inc | Composições e métodos de modulação da excisão-união de smn2 |
| ATE526345T1 (de) | 2005-08-31 | 2011-10-15 | Univ Laval | Antikörper und ihre verwendung bei der behandlung,vorbeugung und diagnose einer mit sod1-anomalien assoziierten krankheit |
| US7846445B2 (en) | 2005-09-27 | 2010-12-07 | Amunix Operating, Inc. | Methods for production of unstructured recombinant polymers and uses thereof |
| US7855279B2 (en) | 2005-09-27 | 2010-12-21 | Amunix Operating, Inc. | Unstructured recombinant polymers and uses thereof |
| HUE033325T2 (en) | 2007-01-05 | 2017-11-28 | Univ Zuerich | Anti-beta-amyloid binder antibodies and their use |
| US8128926B2 (en) | 2007-01-09 | 2012-03-06 | Biogen Idec Ma Inc. | Sp35 antibodies and uses thereof |
| CA2695374A1 (en) | 2007-08-15 | 2009-02-19 | Amunix, Inc. | Compositions and methods for modifying properties of biologically active polypeptides |
| EP2315779A2 (en) | 2008-07-09 | 2011-05-04 | Biogen Idec MA Inc. | Compositions comprising antibodies to lingo or fragments thereof |
| HRP20150831T1 (hr) | 2008-12-19 | 2015-10-09 | Biogen International Neuroscience Gmbh | Humana anti-alfa- sinuklein auto-protutijela |
| JP2012515556A (ja) | 2009-01-23 | 2012-07-12 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | 低下したエフェクタ機能を有する安定化Fcポリペプチドおよび使用方法 |
| DK3178835T3 (da) | 2009-02-03 | 2019-06-24 | Amunix Pharmaceuticals Inc | Forlængede rekombinante polypeptider og sammensætninger omfattende samme |
| US8703717B2 (en) | 2009-02-03 | 2014-04-22 | Amunix Operating Inc. | Growth hormone polypeptides and methods of making and using same |
| US8680050B2 (en) | 2009-02-03 | 2014-03-25 | Amunix Operating Inc. | Growth hormone polypeptides fused to extended recombinant polypeptides and methods of making and using same |
| WO2010144508A1 (en) | 2009-06-08 | 2010-12-16 | Amunix Operating Inc. | Glucose-regulating polypeptides and methods of making and using same |
| PE20121539A1 (es) | 2009-06-08 | 2012-12-06 | Amunix Operating Inc | Polipeptidos de la hormona de crecimiento y metodos de preparacion |
| KR20220084437A (ko) | 2009-06-17 | 2022-06-21 | 바이오젠 엠에이 인코포레이티드 | 대상에게서 smn2 스플라이싱을 조정하기 위한 조성물 및 방법 |
| CA2771999A1 (en) | 2009-08-24 | 2011-03-10 | Amunix Operating Inc. | Coagulation factor vii compositions and methods of making and using same |
| WO2011028344A2 (en) | 2009-08-25 | 2011-03-10 | Amunix Operating Inc. | Interleukin-1 receptor antagonist compositions and methods of making and using same |
| AU2010311332B2 (en) | 2009-10-30 | 2015-04-23 | Albumedix Ltd. | Albumin variants |
| WO2011103076A1 (en) | 2010-02-16 | 2011-08-25 | Medlmmune, Llc | Hsa-related compositions and methods of use |
| PH12012501744A1 (en) * | 2010-03-03 | 2021-08-09 | Boehringer Ingelheim Int | Biparatopic abeta binding polypeptides |
| KR20130070576A (ko) | 2010-04-09 | 2013-06-27 | 노보자임스 바이오파마 디케이 에이/에스 | 알부민 유도체 및 변이체 |
| US20130017997A1 (en) | 2010-08-19 | 2013-01-17 | Amunix Operating Inc. | Factor VIII Compositions and Methods of Making and Using Same |
| LT2627672T (lt) | 2010-10-11 | 2018-12-10 | Biogen International Neuroscience Gmbh | Žmogaus antikūnai prieš tau baltymą |
| WO2012059486A1 (en) | 2010-11-01 | 2012-05-10 | Novozymes Biopharma Dk A/S | Albumin variants |
| CN103380145B (zh) | 2010-12-17 | 2016-10-12 | 生物控股有限公司 | 人类抗-sod1抗体 |
| US9045564B2 (en) | 2011-02-15 | 2015-06-02 | Medimmune, Llc | HSA-related compositions and methods of use |
| EP2675471A4 (en) | 2011-02-15 | 2015-01-28 | Medimmune Llc | HSA-RELATED COMPOSITIONS AND USE PROCESSES |
| WO2012150319A1 (en) | 2011-05-05 | 2012-11-08 | Novozymes Biopharma Dk A/S | Albumin variants |
| PL2723379T3 (pl) | 2011-06-23 | 2019-05-31 | Biogen Int Neuroscience Gmbh | Cząsteczki wiążące przeciwko alfa-synukleinie |
| SI2766397T1 (sl) | 2011-10-11 | 2018-09-28 | F. Hoffmann-La Roche Ag | Izboljšano sestavljanje bispecifičnih protiteles |
| CA2853412C (en) | 2011-10-28 | 2021-05-04 | University Of Zurich | Tdp-43 specific binding molecules |
| CN104159922B (zh) * | 2012-01-10 | 2018-03-02 | 比奥根Ma公司 | 对转运治疗性分子穿过血脑屏障的增强 |
| CN104302408B (zh) | 2012-02-27 | 2016-12-14 | 阿穆尼克斯运营公司 | Xten缀合组合物和制造其的方法 |
| EP2885010B1 (en) | 2012-08-16 | 2020-01-01 | Ipierian, Inc. | Methods of treating a tauopathy |
| JP6284548B2 (ja) | 2012-12-21 | 2018-02-28 | バイオジェン・エムエイ・インコーポレイテッドBiogen MA Inc. | ヒト抗タウ抗体 |
| US8980270B2 (en) | 2013-01-18 | 2015-03-17 | Ipierian, Inc. | Methods of treating a tauopathy |
| AU2014217831A1 (en) | 2013-02-16 | 2015-07-16 | Albumedix Ltd. | Pharmacokinetic animal model |
| KR102042174B1 (ko) * | 2013-03-29 | 2019-11-08 | 삼성전자주식회사 | 인간화 및 친화도 성숙된 항 c-Met 항체 및 그의 용도 |
| WO2014179657A1 (en) | 2013-05-03 | 2014-11-06 | Eleven Biotherapeutics, Inc. | Albumin variants binding to fcrn |
| CA2960925A1 (en) | 2014-09-30 | 2016-04-07 | Neurimmune Holding Ag | Human-derived anti-dipeptide repeats (dprs) antibody |
| EP3233922B1 (en) * | 2014-12-19 | 2022-05-11 | MedImmune Limited | Blood brain barrier transport molecules and uses thereof |
| AU2016210835B2 (en) * | 2015-01-29 | 2021-01-21 | Technophage, Investigação E Desenvolvimento Em Biotecnologia, Sa | Antibody molecules and peptide delivery systems for use in alzheimer's disease and related disorders |
| WO2017106462A1 (en) | 2015-12-18 | 2017-06-22 | Biogen Ma Inc. | Bispecific antibody platform |
| CA3059938A1 (en) * | 2017-04-14 | 2018-10-18 | Kodiak Sciences Inc. | Complement factor d antagonist antibodies and conjugates thereof |
-
2019
- 2019-10-28 MA MA054070A patent/MA54070A/fr unknown
- 2019-10-28 KR KR1020217016206A patent/KR20210111242A/ko not_active Abandoned
- 2019-10-28 MX MX2021004772A patent/MX2021004772A/es unknown
- 2019-10-28 CN CN201980081497.5A patent/CN113508135A/zh active Pending
- 2019-10-28 EA EA202191179A patent/EA202191179A1/ru unknown
- 2019-10-28 US US17/288,445 patent/US20220089704A1/en not_active Abandoned
- 2019-10-28 JP JP2021547670A patent/JP2022509372A/ja active Pending
- 2019-10-28 EP EP19805038.7A patent/EP3873934A2/en active Pending
- 2019-10-28 WO PCT/US2019/058286 patent/WO2020092202A2/en not_active Ceased
- 2019-10-28 CA CA3117409A patent/CA3117409A1/en active Pending
- 2019-10-28 AU AU2019371814A patent/AU2019371814A1/en not_active Abandoned
- 2019-10-28 BR BR112021008105-4A patent/BR112021008105A2/pt not_active IP Right Cessation
-
2021
- 2021-04-27 IL IL282677A patent/IL282677A/en unknown
-
2024
- 2024-10-07 JP JP2024176055A patent/JP2024177499A/ja active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018007950A1 (en) * | 2016-07-06 | 2018-01-11 | National Research Council Of Canada | Humanized antibodies transmigrating the blood-brain barrier and uses thereof |
| WO2018109663A1 (en) * | 2016-12-12 | 2018-06-21 | National Research Council Of Canada | Antibody variants transmigrating the blood-brain barrier and uses thereof |
| WO2018138709A1 (en) * | 2017-01-30 | 2018-08-02 | National Research Council Of Canada | Blood-brain barrier transmigrating compounds and uses thereof |
Non-Patent Citations (1)
| Title |
|---|
| JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 287, JPN6023039098, 2011, pages 1970 - 1979, ISSN: 0005627519 * |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2020092202A9 (en) | 2021-05-14 |
| MX2021004772A (es) | 2021-08-16 |
| BR112021008105A2 (pt) | 2021-08-03 |
| KR20210111242A (ko) | 2021-09-10 |
| JP2024177499A (ja) | 2024-12-19 |
| WO2020092202A2 (en) | 2020-05-07 |
| CN113508135A (zh) | 2021-10-15 |
| MA54070A (fr) | 2021-09-08 |
| IL282677A (en) | 2021-06-30 |
| WO2020092202A3 (en) | 2020-07-23 |
| CA3117409A1 (en) | 2020-05-07 |
| EA202191179A1 (ru) | 2021-09-09 |
| US20220089704A1 (en) | 2022-03-24 |
| EP3873934A2 (en) | 2021-09-08 |
| AU2019371814A1 (en) | 2021-06-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7314356B2 (ja) | 改変j鎖を有する結合分子 | |
| JP2024177499A (ja) | 血液脳関門輸送の促進のためのヒト化され安定化されたfc5バリアント | |
| JP7106234B2 (ja) | 二重特異性抗体を製造する方法、二重特異性抗体及びこのような抗体の治療的使用 | |
| JP7195929B2 (ja) | 三重特異性および/または三価結合タンパク質 | |
| EP3571225B1 (en) | Improved serum albumin binders | |
| JP7785669B2 (ja) | N末端scFv多重特異性結合分子 | |
| JP7195142B2 (ja) | 改善された血清アルブミン結合性免疫グロブリン可変ドメイン | |
| JP2018087211A (ja) | 交差結合領域の配向性を有する二重可変領域抗体様結合タンパク質 | |
| KR20190134997A (ko) | 항-tau 항체 및 이의 사용 방법 | |
| JP2025528797A (ja) | トランスフェリン受容体結合タンパク質及びコンジュゲート | |
| JP2021529796A (ja) | 多特異性Wnt代替分子及びその使用 | |
| JP2022542884A (ja) | Fcrnアンタゴニストで抗体媒介性障害を処置する方法 | |
| CN111886240A (zh) | 血脑屏障迁移化合物及其用途 | |
| JP2021532085A (ja) | CTLA−4を標的とする改変されたFc抗原結合ドメイン構築体に関する組成物および方法 | |
| JP2016027801A (ja) | 改良された抗血清アルブミン結合変異体 | |
| WO2025242094A1 (zh) | 靶向bdca2的抗体或其抗原结合片段及其应用 | |
| US20260035450A1 (en) | Novel anti-angptl3 antibodies suitable for high concentration compositions and subcutaneous administration | |
| CN119698294A (zh) | 结合γ-δT细胞受体的变体抗体 | |
| KR20240005823A (ko) | 다중특이적 fgf21 수용체 효능제 및 그의 용도 | |
| WO2025247301A1 (en) | Novel antibodies specific for cd98 heavy chain and methods of uses thereof | |
| TW202412838A (zh) | 包含結合γ-δ T細胞受體之抗體之組合物 | |
| WO2025253337A2 (en) | Monospecific and bispecific tau binding proteins and compositions thereof | |
| HK40017968A (en) | Improved serum albumin binders | |
| HK40017968B (en) | Improved serum albumin binders |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20221024 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20221024 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230926 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20231220 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20240125 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20240607 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20241007 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20241024 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20241125 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20250226 |